The DOI matches its Crossref record; 86 of the 88 references it cites were found in a registry or an index.
Treatment-resistant anxiety disorders
Abstract
Several epidemiological studies confirmed that Anxiety Disorders as a group are the most prevalent psychiatric conditions in the United States. The importance of these conditions is underlined by the fact that they cause significant disability, poor quality of life, alcohol and drug abuse. Anxiety disorders are treatable conditions and respond to the front-line interventions such as serotonin reuptake inhibitors and cognitive behavioral therapy. However, only about 60% of patients respond to those treatments to any significant degree. Many still have residual symptoms or stay treatment refractory. The group of anxiety patients that is resistant to the treatment has been shown to have very poor quality of life and have highest rate of suicidal attempts than any other disorders. Many biological, treatment specific and social factors are affecting treatment resistance. In this paper, we are attempting to review reasons for the treatment resistance. In addition, we would like to review current strategies that could be helpful in reducing treatment resistance and aiding people chronically suffering from these severe and disabling conditions.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, comorbid anxiety and depression is associated with more severe somatic symptoms, poorer social functioning, greater suicidal ideation and a higher likelihood of prescription of benzodiazepines, as well as poorer treatment response.13,14”
From Acceptance and commitment therapy for older people with treatment-resistant generalised anxiety disorder: The FACTOID feasibility study (2021) · cites this paper as [13]
In the citing paper
“For example, comorbid anxiety and depression is associated with more severe somatic symptoms, poorer social functioning, greater suicidal ideation and a higher likelihood of prescription of benzodiazepines, as well as poorer treatment response.13,14”
From Acceptance and commitment therapy for older people with treatment-resistant generalised anxiety disorder: The FACTOID feasibility study (2021) · cites this paper as [13]
In the citing paper
“Several factors are associated with treatment-resistant anxiety, including comorbid physical and mental health conditions, noncompliance and environmental stressors.13”
From Acceptance and commitment therapy for older people with treatment-resistant generalised anxiety disorder: The FACTOID feasibility study (2021) · cites this paper as [13]
In the citing paper
“Physical and mental health comorbidity (e.g.depression, other anxiety disorders, personality disorders, mild cognitive deficits, physical ill-health, pain) is common in TR-GAD and is associated with poor treatment response.13”
From Acceptance and commitment therapy for older people with treatment-resistant generalised anxiety disorder: The FACTOID feasibility study (2021) · cites this paper as [13]
In the citing paper
“Although treatment for anxiety disorders produces moderate QOL improvements, not all individuals respond to these front-line interventions, and those who are treatment refractory exhibit particularly low QOL and increased rates of suicide [85].”
From Correlates of Quality of Life in Anxiety Disorders: Review of Recent Research (2021) · cites this paper as [85]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Kessler, R. C. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950010008002 · Cited by 12,370
Kessler, R. C., Chiu, W. T., Demler, O., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.617 · Cited by 12,052
Prevalence and Treatment of Mental Disorders, 1990 to 2003
Kessler, R. C., Demler, O., Frank, R. G., Olfson, M., Pincus, H. A., Walters, E. E., Wang, P., Wells, K. B., & Zaslavsky, A. M. (2005) · New England Journal of Medicine · doi:10.1056/nejmsa043266 · Cited by 1,910
The Emotional Brain, Fear, and the Amygdala
LeDoux, J. (2003) · Cellular and Molecular Neurobiology · doi:10.1023/a:1025048802629 · Cited by 1,818
Neuroanatomical Hypothesis of Panic Disorder, Revised
Gorman, J. M., Kent, J. M., Sullivan, G. M., & Coplan, J. D. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.4.493 · Cited by 1,004
Barlow, D. H., Gorman, J. M., Shear, M. K., & Woods, S. W. (2000) · JAMA · doi:10.1001/jama.283.19.2529 · Cited by 953
Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., WFSBP TASK FORCE ON TREATMENT GUIDE, Bandelow, B., Zohar, J., Hollander, E., Kasper, S., et al. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 854
Neuroimaging and frontal–subcortical circuitry in obsessive–compulsive disorder
Saxena, S., Brody, A. L., Schwartz, J. M., & Baxter, L. R. (1998) · British Journal of Psychiatry · doi:10.1192/s0007125000297870 · Cited by 831
Long-term treatment with vagus nerve stimulation in patients with refractory epilepsy
Morris, G. L., Mueller, W. M., & The Vagus Nerve Stimulation Study Group E–E (1999) · Neurology · doi:10.1212/wnl.53.8.1731 · Cited by 724
Groves, D. A., & Brown, V. J. (2005) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2005.01.004 · Cited by 675
Research works printed but not linked: 5
- Nemeroff CB . Remission: today's target in the treatment of mood and anxiety disorders. Psychopharmacol Bull 2002; 36: 5.
- Pollack MH, Meoni P, Otto MW, Simon N, Hackett D . Predictors of outcome following venlafaxine extended-release treatment of DSM-IV generalized anxiety disorder: a pooled analysis of short- and long term studies. J Clin Psychopharmacol 2003; 23: 250–259.
- Barlow DH, Gorman JM, Shear MK, Woods SW . Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial. JAMA 2000; 283: 2529–2536. · DOI · Paper page
- Beale MD, Kellner CH, Pritchett JT, Burns CM . ECT for OCD. J Clin Psychiatry 1995; 56: 81–82.
- Rush AJ, Marangell LB, Sackeim HA, George MS, Brannan SK, Davis SM et al. Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial. Biol Psychiatry 2005; 58: 347–354. · DOI · Paper page
Cited by
Frontal midline theta reflects anxiety and cognitive control: Meta-analytic evidence
Cavanagh, J. F., & Shackman, A. J. (2015) · Journal of Physiology-Paris · doi:10.1016/j.jphysparis.2014.04.003 · Cited by 623
“These psychiatric disorders are highly prevalent, debilitating, and challenging to treat (Bystritsky, 2006; Kessler et al., 2012), underscoring the importance of a deeper understanding of the neural systems that confer liability to dispositional anxiety.”
The neurobiology of depression and antidepressant action
Willner, P., Scheel-Krüger, J., & Belzung, C. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2012.12.007 · Cited by 519
Activation of β-catenin by carcinogenic Helicobacter pylori
Franco, A. T., Israel, D. A., Washington, M. K., Krishna, U., Fox, J. G., Rogers, A. B., Neish, A. S., Collier-Hyams, L., Perez-Perez, G. I., Hatakeyama, M., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504927102 · Cited by 479
Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options
Garakani, A., Murrough, J. W., Freire, R. C., Thom, R. P., Larkin, K., Buono, F. D., & Iosifescu, D. V. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.595584 · Cited by 440
“The literature, however, indicates that only 60–85% of patients with anxiety disorders respond (experience at least a 50% improvement) to current biological and psychological treatments (6).”
BackgroundCandidate biomarkers in psychiatric disorders: state of the field
Abi‐Dargham, A., Moeller, S. J., Ali, F., DeLorenzo, C., Domschke, K., Horga, G., Jutla, A., Kotov, R., Paulus, M. P., Rubio, J. M., et al. (2023) · World Psychiatry · doi:10.1002/wps.21078 · Cited by 372
Metadata
- Authors
- Bystritsky, A.
- Affiliations
- University of California, Los Angeles (US)
- Corresponding author
- Bystritsky, A
- ORCID
- Bystritsky, A
- Venue
- Molecular Psychiatry
- Published
- 2006-07-18
- Volume
- 11
- Issue
- 9
- Pages
- 805-814
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- OpenAlex
- W2004241099
- Cited by
- 289
- References
- 88
- Citations by year
- 2026: 14 · 2025: 24 · 2024: 31 · 2023: 23 · 2022: 23 · 2021: 25 · 2020: 10 · 2019: 22 · 2018: 17 · 2017: 18 · 2016: 22 · 2015: 10 · 2014: 10 · 2013: 8 · 2012: 4
- FWCI
- 0.54
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Molecular Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Clinical Psychology › Psychological Treatments and Disorders
- Keywords
- anxiety disorders, treatment resistance, serotonin reuptake inhibitors, cognitive behavioral therapy, residual symptoms, suicide attempts, quality of life, chronic anxiety, biological factors, social factors
- MeSH terms
- Anxiety Disorders, Humans, United States, Treatment Outcome, Selective Serotonin Reuptake Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment-resistant anxiety disorders. https://app.cochat.ai/papers/10.1038/sj.mp.4001852
- The paper
- Bystritsky, A. (2006). Treatment-resistant anxiety disorders. Molecular Psychiatry. https://doi.org/10.1038/sj.mp.4001852
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.